• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

EL-102

CAS No. 1233948-61-2

EL-102 ( —— )

产品货号. M33349 CAS No. 1233948-61-2

EL-102 是 hypoxia-induced factor 1 (Hif1α) 的抑制剂。EL-102 诱导细胞凋亡,抑制微管蛋白聚合,并显示抗前列腺癌活性。EL-102 可用于癌症的研究。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
2MG ¥1150 有现货
5MG ¥1841 有现货
10MG ¥2972 有现货
25MG ¥4481 有现货
50MG ¥6084 有现货
100MG ¥8874 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    EL-102
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    EL-102 是 hypoxia-induced factor 1 (Hif1α) 的抑制剂。EL-102 诱导细胞凋亡,抑制微管蛋白聚合,并显示抗前列腺癌活性。EL-102 可用于癌症的研究。
  • 产品描述
    EL-102 is a hypoxia-induced factor 1 (Hif1α) inhibitor. EL-102 induces apoptosis, inhibits tubulin polymerisation and shows activities against prostate cancer. EL-102 can be used for the research of cancer.
  • 体外实验
    EL-102 (0-120 nM; 72 h) inhibits prostate cancer cells proliferation in vitro.EL-102 (0-100 nM; 72 h) shows cytotoxicity to prostate cancer cell lines.EL-102 (10-100 nM; 24-72 h) induces cellular apoptosis and affects cell cycle.EL-102 (10-100 nM; 24-48 h) affects PARP cleavage in DU145 cells.EL-102 (5 nM; 0-60 min) inhibits tubulin polymerisation activity.EL-102 (0-100 nM; 1 hour) inhibits Hif1α protein expression.Cell Proliferation Assay Cell Line:CWR22, 22Rv1, DU145, PC-3, DLKP and DLKPA cell lines Concentration:0-120 nM Incubation Time:72 hours Result:Inhibited proliferation of CWR22, 22Rv1, DU145, PC-3, DLKP and doxorubicin-selected variant DLKPA cells with IC50s of 24, 21.7, 40.3, 37.0, 14.4 and 16.3 nM, respectively.Cell Cytotoxicity Assay Cell Line:CWR22, 22Rv1, DU145 and PC-3 cell lines Concentration:0-100 nM Incubation Time:72 hoursResult:Exibited cytotoxicity to prostate cancer cell lines, and showed no additive effect on the inhibition of cell viability with docetaxel.Apoptosis Analysis Cell Line:CWR22, 22Rv1, DU145, PC-3, DLKP and DLKPA cell lines Concentration:10 and 100 nM Incubation Time:24, 48 and 72 hours Result:Induced cell apoptosis to inhibits cell viability with a dose of 100 nM.Western Blot Analysis Cell Line:DU145 cell line Concentration:10 and 100 nM Incubation Time:24 and 48 hours Result:Increased PARP cleavage in DU145 cells and showed a more dramatic effect with docetaxel adding.Cell Cycle Analysis Cell Line:DU145 cell line Concentration:10 and 100 nM Incubation Time:24, 48 and 72 hours Result:Increased loss of cells from G1 phase and accumulated cells in G2/M phase.Western Blot Analysis Cell Line:Prostate cancer cells Concentration:10 , 50 and 100 nM Incubation Time:24 and 48 hours Result:Modestly inhibited Hif1α expression at doses of 50 and 100 nM in normoxia.
  • 体内实验
    EL-102 (12 and 15 mg/kg; p.o. 5-day on and 2-day off, from 13 to 37 days after tumour transplantation) potentiates effects of docetaxel in vivo.Animal Model:Nude mice with CWR22 xenografts Dosage:12 and 15 mg/kg Administration:Oral gavage; 12 and 15 mg/kg 5-day on and 2-day off; from 13 to 37 days after tumour transplantation Result:Showed no effect on tumor growth, but enhanced the effect of docetaxel on tumor .
  • 同义词
    ——
  • 通路
    Others
  • 靶点
    Other Targets
  • 受体
    Microtubule Associated | HIF
  • 研究领域
    ——
  • 适应症
    ——

化学信息

  • CAS Number
    1233948-61-2
  • 分子量
    384.47
  • 分子式
    C19H16N2O3S2
  • 纯度
    >98% (HPLC)
  • 溶解度
    In Vitro:?DMSO 中的溶解度 : ≥ 36 mg/mL (93.64 mM)
  • SMILES
    COc1ccc(cc1)S(=O)(=O)Nc1cc(ccc1C)-c1csc(c1)C#N
  • 化学全称
    ——

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1. A P Toner et al. The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivoactivity against prostate cancer and circumvents MDR1 resistance. Br J Cancer, 2013 Oct 15, 109(8): 2131-2141.?
产品手册
关联产品
  • 21,28-Epoxy-25,28-di...

    21,28-Epoxy-25,28-dihydroxy-precyasterone

  • STC314

    STC314 是一种与组蛋白发生静电相互作用的小聚阴离子。STC314 阻断组蛋白对脂质双层的破坏,从而抑制组蛋白的细胞毒性、血小板活化和红细胞损伤作用。STC314 具有抗感染作用,可用于脓毒症研究。

  • MAO-B-IN-5

    MAO-B-IN-5 是一种有效的、选择性和具有口服活性的 MAO-B 抑制剂,IC50 值为 0.204 μM。MAO-B-IN-5 具有研究帕金森病 (PD) 的潜力。